{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:38Z","timestamp":1791521438936,"version":"4.3.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>New methods are pivotal in accurately predicting, monitoring, and diagnosing the clinical manifestation of type 1 diabetes (T1D) in high-risk children. Continuous glucose monitoring (CGM) is a valuable tool for patients with T1D, but there is still a knowledge gap regarding its utility in the prediction of diabetes. The current study explored whether 10-day CGM or CGM during an oral glucose tolerance test (OGTT) performed in the laboratory or at home (home-OGTT) could be accurate in detecting stages of T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research Design and Methods:<\/jats:title>\n                    <jats:p>Forty-six subjects 4\u201325 years of age carrying genetic risk for T1D were recruited and classified into the following groups: islet autoantibody (IAb) negative, one IAb, and stages 1\u20133 of T1D, based on the laboratory OGTT and IAb results at baseline. A 10-day CGM was initiated before the OGTT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this study, we showed that CGM was sensitive in detecting asymptomatic individuals at stage 3, and dysglycemic individuals in stage 2 of T1D both during OGTT and the 10-day period. CGM also showed significant differences in several variables during the 10-day sensoring among individuals at different stages of T1D. Furthermore, CGM showed different OGTT profiles and detected significantly more abnormal OGTT results when compared with plasma glucose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CGM together with home-OGTT could detect stages of T1D and offer an alternative method to confirm normoglycemia in high-risk individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2021.0554","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T16:59:32Z","timestamp":1654189172000},"page":"655-665","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0781-6286","authenticated-orcid":false,"given":"Helena","family":"Kontola","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka","family":"Alanko","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko J.","family":"Koskenniemi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Turku University Hospital, Turku, Finland."},{"name":"Research Center for Integrative Physiology and Pharmacology, and Center for Population Health Research, Institute of Biomedicine, University of Turku, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliisa","family":"L\u00f6yttyniemi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Turku, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Itoshima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Turku University Hospital, Turku, Finland."},{"name":"Research Center for Integrative Physiology and Pharmacology, and Center for Population Health Research, Institute of Biomedicine, University of Turku, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Knip","sequence":"additional","affiliation":[{"name":"Pediatric Research Center, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland."},{"name":"Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland."},{"name":"Center for Child Health Research, Tampere University Hospital, Tampere, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Veijola","sequence":"additional","affiliation":[{"name":"Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland."},{"name":"PEDEGO Research Unit, Department of Pediatrics, Medical Research Center, University of Oulu, Oulu, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"Toppari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Turku University Hospital, Turku, Finland."},{"name":"Research Center for Integrative Physiology and Pharmacology, and Center for Population Health Research, Institute of Biomedicine, University of Turku, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Kero","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Turku University Hospital, Turku, Finland."},{"name":"Research Center for Integrative Physiology and Pharmacology, and Center for Population Health Research, Institute of Biomedicine, University of Turku, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.6285"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1836"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2088"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00070"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0674"},{"key":"e_1_3_6_7_2","article-title":"Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA","volume":"4","author":"M\u00e5nsson Martinez M","year":"2020","unstructured":"M\u00e5nsson Martinez M, , Salami F, , Helena EL, et al.: Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA. Endocrinol Diab Metab, 2020; 4:e00198.","journal-title":"Endocrinol Diab Metab"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0497"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.07.027"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1770"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12541"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.10.005"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6940"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02196"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1419"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051616"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050925"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051067"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2440"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1371"},{"key":"e_1_3_6_22_2","first-page":"870","article-title":"Triple-label hybridization assay for type-1 diabetes-related HLA alleles","volume":"18","author":"Sj\u00f6roos M","year":"1995","unstructured":"Sj\u00f6roos M, , Iiti\u00e4 A, , Ilonen J, et al.: Triple-label hybridization assay for type-1 diabetes-related HLA alleles. Biotechniques, 1995; 18:870\u2013877.","journal-title":"Biotechniques"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12327"},{"key":"e_1_3_6_24_2","unstructured":"World Health Organization & International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO\/IDF Consultation. Geneva Switzerland: World Health Organization 2006."},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S062"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7244.1240"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.44.235.291"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2012.08.001"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02763"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248560"},{"key":"e_1_3_6_31_2","unstructured":"Motulsky HJ : GraphPad Statistics Guide. www.graphpad.com\/guides\/prism\/9\/statistics\/index.htm (accessed May17 2022)."},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/193229680900300528"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0150"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296815590154"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0143"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13149"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2021.0554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:13:35Z","timestamp":1777400015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2021.0554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1089\/dia.2021.0554"],"URL":"https:\/\/doi.org\/10.1089\/dia.2021.0554","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}